These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 1477486)

  • 21. Prevalence and pattern of drug treatment for behavior and seizure disorders of TMR students.
    Gadow KD; Kalachnik J
    Am J Ment Defic; 1981 May; 85(6):588-95. PubMed ID: 7270572
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Behavior disorders in persons with mental retardation receiving antipsychotic medication.
    Ono Y
    Res Dev Disabil; 1998; 19(2):123-30. PubMed ID: 9547524
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Olanzapine for self-injurious, aggressive, and disruptive behaviors in intellectually disabled adults: a retrospective, open-label, naturalistic trial.
    Janowsky DS; Barnhill LJ; Davis JM
    J Clin Psychiatry; 2003 Oct; 64(10):1258-65. PubMed ID: 14658977
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A study of the prescribing for people with learning disabilities living in the community and in National Health Service care.
    Branford D
    J Intellect Disabil Res; 1994 Dec; 38 ( Pt 6)():577-86. PubMed ID: 7881229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medication use among Australian adults with intellectual disability in primary healthcare settings: a cross-sectional study.
    Doan TN; Lennox NG; Taylor-Gomez M; Ware RS
    J Intellect Dev Disabil; 2013 Jun; 38(2):177-81. PubMed ID: 23550741
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of rationalizing drug treatment of patients with epilepsy and mental retardation.
    Beghi E; Bollini P; Di Mascio R; Cerisola N; Merloni T; Manghi E
    Dev Med Child Neurol; 1987 Jun; 29(3):363-9. PubMed ID: 3596072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A survey of psychotropic medication in mental retardation facilities.
    Tu JB
    J Clin Psychiatry; 1979 Mar; 40(3):125-8. PubMed ID: 33967
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new drug suitable for children and young people with epilepsy and intellectual impairments.
    Leary PM; Allie S
    Dev Med Child Neurol; 1995 Apr; 37(4):371. PubMed ID: 7698529
    [No Abstract]   [Full Text] [Related]  

  • 29. Characteristics and the trajectory of psychotropic medication use in general and antipsychotics in particular among adults with an intellectual disability who exhibit aggressive behaviour.
    Deb S; Unwin G; Deb T
    J Intellect Disabil Res; 2015 Jan; 59(1):11-25. PubMed ID: 24450426
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Challenging behavior in adults with epilepsy and intellectual disability: An analysis of epilepsy characteristics.
    van Ool JS; Snoeijen-Schouwenaars FM; Tan IY; Jurgen Schelhaas H; Aldenkamp AP; Hendriksen JGM
    Epilepsy Behav; 2018 Sep; 86():72-78. PubMed ID: 30153936
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuroleptic and antiepileptic treatment in the mentally retarded.
    Brodtkorb E; Sand T; Strandjord RE
    Seizure; 1993 Sep; 2(3):205-11. PubMed ID: 7909268
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Prevalence of psychotropic and anti-epileptic drug use in mentally handicapped students].
    Meins W
    Z Kinder Jugendpsychiatr; 1991 Mar; 19(1):15-8. PubMed ID: 1927052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reduction of polypharmacy for epilepsy in an institution for the retarded.
    Bennett HS; Dunlop T; Ziring P
    Dev Med Child Neurol; 1983 Dec; 25(6):735-7. PubMed ID: 6653906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Topiramate-induced weight loss depends on level of intellectual disability in patients with epilepsy.
    Iwaki H; Jin K; Fujikawa M; Nakasato N; Kaneko S
    Epilepsy Behav; 2018 Jun; 83():87-91. PubMed ID: 29665571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Psychotropic Prescribing Practices for Children and Adolescents with Intellectual Disabilities: A Cohort Study Using a Large-scale Health Insurance Database].
    Inoue Y; Okumura Y; Fujita J
    Seishin Shinkeigaku Zasshi; 2016; 118(11):823-833. PubMed ID: 30620838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of perampanel in patients with intellectual disability and epilepsy.
    Snoeijen-Schouwenaars FM; van Ool JS; Tan IY; Schelhaas HJ; Majoie MH
    Epilepsy Behav; 2017 Jan; 66():64-67. PubMed ID: 28038388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Topiramate in patients with epilepsy and intellectual disability.
    Martin P; Schreiner A; Rettig K; Schäuble B
    Epilepsy Behav; 2009 Mar; 14(3):496-502. PubMed ID: 19162230
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psychotropic drug use in older developmentally disabled with behavioral difficulties.
    Harper DC; Wadsworth JS; Michael AL
    Res Dev Disabil; 1989; 10(1):53-60. PubMed ID: 2928579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structured Medication Review to Improve Pharmacotherapy in People with Intellectual Disability and Behavioural Problems.
    Scheifes A; Egberts TC; Stolker JJ; Nijman HL; Heerdink ER
    J Appl Res Intellect Disabil; 2016 Jul; 29(4):346-55. PubMed ID: 25882186
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential Risk of Increasing Psychotropic Polypharmacy Use in Children Diagnosed With ADHD as Preschoolers.
    Winterstein AG; Soria-Saucedo R; Gerhard T; Correll CU; Olfson M
    J Clin Psychiatry; 2017 Jul; 78(7):e744-e781. PubMed ID: 28686819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.